Sierra Oncology, Inc.

Sierra Oncology, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with GSK plc, from which it inherits various climate commitments and initiatives.

Sierra Oncology's climate commitments are aligned with those of GSK plc, which has established significant reduction targets and initiatives. These include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all aimed at reducing carbon emissions and promoting sustainability. The specific targets and achievements of these initiatives are cascaded from GSK plc, reflecting a commitment to addressing climate change at a corporate level.

While Sierra Oncology does not have its own emissions data, it is positioned within a framework that prioritises climate action and sustainability, guided by the overarching goals set by GSK plc. This relationship underscores the importance of corporate responsibility in mitigating climate impacts within the pharmaceutical industry.